Axa S.A. Voyager Therapeutics, Inc. Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$7.55 - $11.25 $747,450 - $1.11 Million	99,000 New	99,000 $767,000
Q1 2021 May 14, 2021	SELL	$4.61 - $9.04 $70,072 - $137,408	-15,200 Reduced 8.01%	174,500 $822,000
Q4 2020 Feb 12, 2021	SELL	$7.15 - $12.28 $12,870 - $22,104	-1,800 Reduced 0.94%	189,700 $1.36 Million
Q3 2020 Nov 13, 2020	SELL	$10.01 - $13.75 $17,017 - $23,375	-1,700 Reduced 0.88%	191,500 $2.04 Million
Q2 2020 Aug 14, 2020	BUY	$8.05 - $14.21 $1.46 Million - $2.58 Million	181,700 Added 1580.0%	193,200 $2.44 Million
Q1 2020 May 15, 2020	BUY	$6.8 - $14.66 $4,080 - $8,796	600 Added 5.5%	11,500 $105,000
Q4 2019 Feb 18, 2020	BUY	$12.82 - $16.85 $139,738 - $183,665	10,900 New	10,900 $152,000
Q3 2018 Nov 08, 2018	SELL	$17.11 - $21.74 $473,228 - $601,284	-27,658 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$16.76 - $23.92 $4.03 Million - $5.75 Million	-240,372 Reduced 89.68%	27,658 $540,000
Q1 2018 May 14, 2018	SELL	$16.16 - $31.31 $1.11 Million - $2.15 Million	-68,777 Reduced 20.42%	268,030 $5.04 Million
Q4 2017 Feb 13, 2018	BUY	$12.26 - $25.88 $4.13 Million - $8.72 Million	336,807	336,807 $5.59 Million

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.